Sign Out
Pregnancy: Only limited data on the safety of fosfomycin trometamol treatment during 1st trimester of pregnancy (n=152) are available. These data do not raise any safety signal for teratogenicity so far. Fosfomycin crosses the placenta. Animal studies have not indicated any direct or indirect toxicity with any effect on pregnancy, embryonic development, development of the foetus and/or postnatal development.
Monurol should only be used during pregnancy, if clearly necessary.
Lactation: Since Monurol passes into breast milk even after taking just a single dose, women who are breast-feeding should not be treated with Monurol unless strictly necessary.
Fertility: No data in humans are available. In male and female rats, oral administration of fosfomycin up to 1000 mg/kg/d did not impair fertility.
